



Patient Information Guide

A non-invasive gene expression test for heart transplant patients

AlloMap[®]
MOLECULAR EXPRESSION TESTING

AlloMap[®]

MOLECULAR EXPRESSION TESTING

What is AlloMap?

AlloMap is a non-invasive test that uses a blood sample to help doctors manage the care of stable heart transplant recipients.

AlloMap has been commercially available since 2005 and was cleared by the FDA in 2008.

AlloMap is part of the recommended guidelines for the care of heart transplant recipients issued by the International Society of Heart and Lung Transplantation.¹

1. Costanzo MR et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010 Aug;29(8):914-56.



“AlloMap is setting a new standard for the management of our heart transplant patients because it truly does give you another tool to be able to manage those patients.”

– Transplant Clinician at leading medical center



What does AlloMap do?

- AlloMap testing measures the expression levels of specific genes found in your blood
- The combined level of expression of these genes, represented as an AlloMap test score, can help provide your doctor with additional information regarding your body's response to your transplanted heart
- When used together with standard clinical assessment, AlloMap can help inform your doctor whether you are at low probability of rejecting your heart at the time your blood was drawn

How does AlloMap help me?

AlloMap testing, together with other clinical assessments, helps you in the following ways:

- Uses a simple, non-invasive method of blood sample collection
- Delivers an objective score and additional information to help your doctor evaluate your body's response to your transplanted heart
- Provides an additional and valuable tool for your physician to manage your care after your transplant



Who is X Dx?

X Dx, a life sciences company based in Brisbane, California, is dedicated to improving the standard of care given to heart transplant patients with AlloMap, a non-invasive gene expression test.


How do I get AlloMap Testing?

Talk to your doctor about making AlloMap testing part of your transplant care. If AlloMap is right for you, your doctor will:

- Direct you to your local qualified draw site for you to provide a blood sample
- Order the draw site to collect, process, and send your blood sample for analysis
- Receive your AlloMap test results usually within 2 days after your blood test

AlloMap Testing Process

The sample for AlloMap testing can be obtained from a routine blood test which is shipped to the X Dx Reference Laboratory for analysis. Your doctor will notify you of results.



Is the AlloMap test covered by my insurance provider?

- A growing number of insurance companies are reimbursing for the cost of AlloMap testing
- X Dx has a **Patient Advocacy Team** who works closely with patients, clinicians, and insurance companies to obtain positive reimbursement through accurate billing and appeals
- X Dx is happy to provide assistance and call insurers who may not be aware of the benefits of AlloMap testing to ensure proper reimbursement

What if I have questions about the testing process, insurance, or anything related to AlloMap?

X Dx has a dedicated team of customer service representatives available to assist in answering your general questions and billing-related queries. Please contact Customer Service at **1-888-ALLOMAP (1-888-255-6627)** to reach an X Dx Patient Advocate or to get additional information.

AlloMap[®]
MOLECULAR EXPRESSION TESTING

21,000 tests

7,000 patients

100 centers

AlloMap[®]

MOLECULAR EXPRESSION TESTING

- Since 2005, the AlloMap test has been used more than **21,000** times, in over **7,000** patients, across **100** centers
- Please visit www.allomap.com to hear how doctors and nurses are using AlloMap in their clinical practice

AlloMap[®] Testing Intended Use

AlloMap Molecular Expression Testing is an In Vitro Diagnostic Multivariate Index Assay (IVDMIA) test service, performed in a single laboratory, assessing the gene expression profile of RNA isolated from peripheral blood mononuclear cells (PBMC). AlloMap Testing is intended to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection (ACR) at the time of testing in conjunction with standard clinical assessment. The AlloMap test is indicated for heart transplant recipients 15 years of age or older who are at least two months (≥55 days) post transplant.

XDx

3260 Bayshore Blvd., Brisbane, CA 94005

Phone: 1.888.ALLOMAP (1.888.255.6627)

Fax: 415.287.2456

www.allomap.com

